News >

Role of MRD Still Evolving Across Hematologic Cancers

Jessica Hergert
Published: Thursday, Oct 10, 2019

Imad Tabbara, MD

Imad Tabbara, MD

Novel therapeutic advances in multiple myeloma, acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML) have led to a rapid evolution of disease management, which has increased the focus on the appropriate role of minimal residual disease (MRD) as a prognosis predictor, said Imad Tabbara, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication